1. Pink Sheet
  2. >>Compliance

CDER Laments Lack Of Shortage Funding, But FDA Didn’t Request New Money For 2024

 
• By Sarah Karlin-Smith

CDER head is worried FDA won’t be able to sustain gains the agency made on drug shortages and supply chain work as big CARES Act boost set to run out this year, yet it didn’t ask Congress for new taxpayer funding in the fiscal year 2024 budget request.

PS2304_cavazzoni_drug_shortage
Director Patrizia Cavazzoni said FDA has money to pay inspectors, but has seen 'a lot of attrition.' • Source: Nielsen Hobbs; the Pink Sheet | Shutterstock images

The US Food and Drug Administration is concerned about an upcoming falloff in funding for drug shortage work as it faces a rise in shortages due to an increasingly complex supply chain, Center for Drug Evaluation and Research Director Patrizia Cavazzoni said.

CDER has spent $10m of the $14m Congress gave it to support drug shortages work in the 2020 COVID-19 pandemic legislation called the CARES Act

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Distribution/Supply Chain

More from Compliance

Switzerland Simplifies Imports Of Unauthorized Drugs To Tackle Drug Shortages

 
• By Eliza Slawther

Swiss authorities have introduced temporary measures that will make it easier for health care professionals to import medicines that are either not authorized or not available in Switzerland, which will particularly benefit pediatric drugs, in light of ongoing shortages.

Aragen’s CEO Says NIH Funding Cut Means Less R&D Money, And Tariffs Would Add To Woes

 
• By Vibha Ravi

Aragen’s CEO Manni Kantipudi, who is keenly watching the Trump Administration’s moves on pharma tariffs, discusses funding cuts at the National Institutes of Health, big pharma’s US onshoring moves, and talks with the Indian government to solve intellectual property challenges in an audio interview.

US FDA Retirements Continue Unabated With Drug Inspectorate Leaders, Former Chief Counsel

 
• By Sue Sutter and Derrick Gingery

Alonza Cruse, director of the Office of Human and Animal Drugs Inspectorate, and two other senior inspection officials are departing, along with Mark Raza, chief counsel from 2021 until January.